newsfilter
← Latest News
Business Wire·

Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through